Drug Trial Radar · NCT06154343
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 23, 2022
Primary completion
Dec 31, 2024
Study completion Jul 30, 2025
Sponsor
- Lead sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Conditions
- HER2 Expressing or Mutated Advanced Malignant Solid Tumors
Interventions
GQ1005Drug
an antibody drug conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs)Time frame: Up to 2 years
- Dose Limiting Toxicities (DLTs)Time frame: From first dose to the end of Cycle 1, 21 days
- Maximal Tolerance Dose (MTD) or recommended phase II dose (RP2D)Time frame: After each cohort completes the DLT observation period (Day 1 to Day 21 after the first dose of study treatment) or has a DLT or becomes not DLT-evaluable
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Chinese PLA general hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Haerbin Medical University
Haerbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Affiliated Drum Tower Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China · Recruiting
Shengjing hospital of China medical universty
Shenyang, Liaoning, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, China · Recruiting
Fudan university Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of Xi'an University
Xi'an, Shangxi, China · Recruiting
Suining Central Hospital
Suining, Sichuan, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuang, China · Recruiting
Tianjin medical university cancer institute & hospital
Tianjin, Tianjin Municipality, China · Recruiting
Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.